← boardnext 2026-12
MNPR
Monopar Therapeuticsdistress 1/10 · well-funded / low risk$102.55-9%today-10% from 52w high
Oncology 1
Lead: Wilson disease
Revenue
pre-revenue
Liquidity
$53M
Runway
5.3 yrs
Shares 1y
+9%
Price & events
+42.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-8.8%
1D
-5.5%
1W
+25.4%
1M
+92.6%
3M
+36.7%
6M
+118.8%
1Y
+3104.7%
2Y
+269.5%
5Y
+222.5%
All
Overview
- Market Cap
- $686.99M
- Volume
- 19.38K
- 52 Week Range
- $30.42 – $114
- Total Shares
- 6.70M
- Float Shares
- 4.12M
- Short %
- 33.23%
- % Held by Insiders
- 23.42%
- % Held by Institutions
- 93.31%
- RVOL
- 0.10x
- Beta
- 1.48
Pipeline stages · 1 programs
MNPR-101-PCTA-177Lu
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2026-12-31 | Phase 1 | MNPR-101-PCTA-177Lu | Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer | — | recruiting |
| 2026-04 | Phase 1 | MNPR-101-DFO*-89Zr | Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer | 12 | recruiting |
Catalyst news & presentations · 6
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- June 27-30, 2026conferencedata presentationsecondaryPhase 3ALXN1840 · Presentation of new analyses from Phase 3 FoCus trial showing greater neurologic and global clinical benefit versus standard of careSEC 8-K
- AASLD 2025conferencedata presentationsecondaryPhase 2ALXN1840 · Presentation of new data and analyses from Phase 2 ALXN1840-WD-204 copper balance study at AASLD 2025.SEC 8-K
- September 14-15, 2025conferencedata presentationsecondaryALXN1840 · Long-term neurological efficacy and safety data presented at ANA Annual MeetingSEC 8-K
- EASL International Liver Congress 2025conferencedata presentationsecondaryALXN1840 · Poster presentation of long-term efficacy and safety dataSEC 8-K
- 2024-10-23partnershipALXN-1840 · Licensed ALXN-1840 from Alexion for worldwide development and commercializationSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $114 (+11% upside) · 13 analysts
- 2026-06-30BTIGBuy
- 2026-06-29HC Wainwright & Co.Buy
- 2026-03-30Chardan CapitalBuy
- 2026-02-23BTIGBuy
- 2026-02-02BTIGBuy
- 2026-01-29Chardan CapitalBuy
Competitors — Wilson disease
Recent news
- 2026-07-23H.C. Wainwright raises Monopar stock price target to $125 on NDA filing - Investing.com
- 2026-07-23MNPR Maintained by HC Wainwright & Co. -- Price Target Raised to $125 - GuruFocus
- 2026-07-22Monopar Therapeutics (MNPR) Proxy Filing Summary - Quartr
- 2026-07-22Monopar Files Rolling NDA for ALXN1840 in Wilson Disease - HCP Live
- 2026-07-22Monopar Therapeutics Begins Rolling Application for ALXN1840 in Wilson Disease - Moomoo
- 2026-07-22Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease - The Manila Times
- 2026-07-21Monopar adds commercial leaders ahead of drug filing By Investing.com - Investing.com Nigeria
- 2026-07-20MNPR stock draws attention as Monopar Therapeutics advances pipeline and reports recent financing me - Ad-hoc-news.de
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.